Functional screening in human HSPCs identifies optimized protein-based enhancers of Homology Directed Repair
-
Published:2024-03-23
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Perez-Bermejo Juan A.ORCID, Efagene Oghene, Matern William M.ORCID, Holden Jeffrey K., Kabir Shaheen, Chew Glen M.ORCID, Andreoletti GaiaORCID, Catton Eniola, Ennis Craig L., Garcia Angelica, Gerstenberg Trevor L., Hill Kaisle A., Jain Aayami, Krassovsky Kristina, Lalisan Cassandra D., Lord Daniel, Quejarro B. Joy, Sales-Lee Jade, Shah Meet, Silva Brian J.ORCID, Skowronski Jason, Strukov Yuri G., Thomas Joshua, Veraz Michael, Vijay Twaritha, Wallace Kirby A., Yuan YueORCID, Grogan Jane L.ORCID, Wienert Beeke, Lahiri Premanjali, Treusch Sebastian, Dever Daniel P., Soros Vanessa B., Partridge James R., Seim Kristen L.ORCID
Abstract
AbstractHomology Directed Repair (HDR) enables precise genome editing, but the implementation of HDR-based therapies is hindered by limited efficiency in comparison to methods that exploit alternative DNA repair routes, such as Non-Homologous End Joining (NHEJ). In this study, we develop a functional, pooled screening platform to identify protein-based reagents that improve HDR in human hematopoietic stem and progenitor cells (HSPCs). We leverage this screening platform to explore sequence diversity at the binding interface of the NHEJ inhibitor i53 and its target, 53BP1, identifying optimized variants that enable new intermolecular bonds and robustly increase HDR. We show that these variants specifically reduce insertion-deletion outcomes without increasing off-target editing, synergize with a DNAPK inhibitor molecule, and can be applied at manufacturing scale to increase the fraction of cells bearing repaired alleles. This screening platform can enable the discovery of future gene editing reagents that improve HDR outcomes.
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229–236 (2020). 2. Porteus, M. H. A new class of medicines through DNA editing. N. Engl. J. Med. 380, 947–959 (2019). 3. Morgan, R. A., Gray, D., Lomova, A. & Kohn, D. B. Hematopoietic stem cell gene therapy: progress and lessons learned. Cell Stem Cell 21, 574–590 (2017). 4. Kohn, L. A. & Kohn, D. B. Gene therapies for primary immune deficiencies. Front. Immunol. 12, 648951 (2021). 5. Ferrari, G., Thrasher, A. J. & Aiuti, A. Gene therapy using haematopoietic stem and progenitor cells. Nat. Rev. Genet. 22, 216–234 (2021).
|
|